If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine injection)
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
BASAGLAR® (insulin glargine injection): Transitioning From Basal Insulin
If transitioning from another basal insulin to Basaglar, the recommended initial Basaglar dose is based on the insulin therapy that is being discontinued.
Transitioning From Another Basal Insulin to Basaglar Therapy
If transitioning patients from another basal insulin to Basaglar therapy, the recommended initial dose of Basaglar is based on the insulin therapy that is being discontinued (Table 1. Transitioning From Another Basal Insulin to Basaglar Therapy). Reductions in the Basaglar dose when transitioning from certain insulins will lower the likelihood of hypoglycemia.1
Table 1. Transitioning From Another Basal Insulin to Basaglar Therapy1
|
If transitioning from… |
To… |
Then, the recommended initial dose of Basaglar… |
Example |
|
Lantus |
Basaglar |
is the same as the Lantus dose. |
50 units of Lantus transitions to 50 units of Basaglar |
|
Toujeo |
Basaglar |
is 80% of the Toujeo dose. |
50 units of Toujeo transitions to 40 units of Basaglar |
|
twice-daily NPH insulin |
once-daily Basaglar |
is 80% of the total daily NPH insulin dosage. |
25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 40 units of Basaglar once daily |
|
an intermediate- or long-acting insulin other than Lantus |
Basaglar |
may differ from the prior basal insulin dose and other concomitant antihyperglycemic medications may need to be adjusted. |
… |
Abbreviations: Basaglar = Basaglar® (insulin glargine injection) 100 units/mL; Lantus = Lantus® (insulin glargine injection) 100 units/mL; Toujeo = Toujeo® (insulin glargine injection) 300 units/mL.
Enclosed Prescribing Information
BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly
1. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Glossary
Basaglar = Basaglar® (insulin glargine injection) 100 units/mL
Date of Last Review: November 13, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
